title: Age-related macular degeneration: clinical findings, histopathology and imaging techniques.
abstract: Age-related macular degeneration (AMD) is the most common cause of blindness among people over age 55 years in industrialized countries. Known major risk factors for AMD include: age >55 years, history of smoking, white race, and mutations in various components of the complement system. Early AMD is characterized by the presence of drusen and pigmentary abnormalities. Late AMD is associated with central visual loss and is characterized by the presence of choroidal neovascularization and/or geographic atrophy. Early AMD is associated with a number of biochemical abnormalities including oxidative damage to retinal pigment epithelium (RPE) cells, complement deposition in the RPE-Bruch's membrane-choriocapillaris complex, lipidization of Bruch's membrane, and extracellular matrix abnormalities (e.g. collagen crosslinking, advanced glycation end product formation). Antiangiogenic drugs block the vascular leakage associated with choroidal new vessels, thus reducing retinal edema and stabilizing or restoring vision. At this time, there are no proven effective treatments for the nonexudative complications of AMD. Modern ocular imaging technologies (including spectral domain and phase variance optical coherence tomography, short- and long-wavelength fundus autofluorescence, adaptive optics-scanning laser ophthalmoscopy, and near-infrared reflectance) enable one to follow changes in the RPE, photoreceptors, and choriocapillaris quantitatively as the disease progresses. In addition, one can quantitatively assess the volume of drusen and areas of atrophy. These data, when correlated with the known histopathology of AMD, may provide useful measures of treatment efficacy that are likely to be more sensitive and reproducible than conventional end points such as visual acuity and rate of enlargement of geographic atrophy. As a result, these imaging technologies may be valuable in assessing the effects of cell-based therapy for patients with AMD.
authors.affiliation: Rutgers New Jersey Medical School, Newark, N.J., USA.
authors.forename: Marco A
authors.initials: MA
authors.lastname: Zarbin
authors.forename: Ricardo P
authors.initials: RP
authors.lastname: Casaroli-Marano
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Rosenfeld
mesh_terms: D003952:Diagnostic Imaging / Q000379:methods*; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D014943:Global Health; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis* / Q000453:epidemiology*; D009017:Morbidity / Q000639:trends; D009887:Ophthalmoscopy; D041623:Tomography, Optical Coherence; D014792:Visual Acuity